Between 2.5% and 8.4% of children and adolescents worldwide identify as transgender or gender-diverse and rates are increasing over time.1  This increase is accompanied by a rise in the number of families seeking advice on how to address gender concerns among their children and adolescents.24  Many providers have limited experience caring for this population and it can be difficult for them to provide advice and treatment.57 

A number of effective interventions are available to assist transgender children and adolescents. Parental support for social transition, which can include changing the youth’s hair, clothes, behavior, pronouns, and/or name to better align with the patient’s perceived gender identity, is associated with improved emotional outcomes.810  Use of gonadotropin-releasing hormone analogs to temporarily pause further development in peripubertal youth and give them time to explore and confirm their gender identity before starting any other treatments is associated with improved global functioning, reductions in behavioral and emotional problems, and decreased rates of depression and suicidal ideation among transgender and gender-diverse youth who have not completed puberty.911  Gender-affirming hormones can help older adolescents align their body and experienced gender, producing improved quality of life, body satisfaction, and mental health among transgender youth.1215  However, use of gender-affirming hormones is associated with permanent changes to the patient’s fertility and appearance and is restricted to adolescents who can understand the risks and benefits of gender-affirming hormones.9,10  Treatment guidelines suggest that almost all adolescents have the mental capacity to provide informed consent to treatments with irreversible effects by age 16, and some patients as young as 14 can demonstrate this capacity.9,13,16,17 

Despite efforts to help patients and families to balance the risks and benefits of treatment and protect adolescents from harm, some youth will experience a change in gender identity after starting gender-affirming hormones and express regret over the irreversible effects of treatment. Concern over future regret has led some providers to object to gender-affirming treatment and question the ability of minors to truly consent/assent to these treatments.18  Some members of the judiciary in the United Kingdom and United States state legislatures have expressed similar concerns and restricted or prohibited access to gender-affirming care for minors.19,20  For example, 3 states in the United States have passed laws prohibiting gender-affirming medical care for minors and 21 others are considering similar laws.

Estimating the long-term risks associated with treatment is difficult because it is unclear how often patients experience regret after treatment. Studies examining persistence of gender identity found that only 20% of youth engaged in gender-nonconforming behavior before puberty will report a transgender gender identity as an adult, suggesting that gender identity can be transient during childhood and adolescence.2124  Persistence is associated with increased intensity of gender-related dysphoria, assertion of gender identity cognitively versus affectively, and degree of social transition.2125  Among prepubertal transgender patients, 100% of patients with a complete social transition, 60.1% with a partial transition, and 25.6% of patients who had not socially transitioned reported a transgender identity 7 years later.22,23 

Among adults with a history of gender-nonconforming behavior during childhood, both cis-gender and transgender adults identified at age 10 to 13 years, the typical onset of puberty, as a key time for consolidation of gender identity, with few changes occurring after this time.22,23 Among peri- or postpubertal transgender youth receiving gender-affirming medications at specialized gender clinics, 1.9% to 3.5% of patients discontinued treatment.9,11,26,27  Among adolescents obtaining gender-affirming hormones from the United States Military Health System, 25.6% stopped treatment within 4 years of starting.28  These studies did not assess reasons for discontinuing treatment.

Most adults who stop gender-affirming hormones report doing so for reasons unrelated to a change in gender identity, such as pressure from family, difficulty obtaining employment, or discrimination.26  Also, some patients who experience a change in gender identity and stop treatment do not express regret with the experience.2931 

Reports of increased stability of gender identity after puberty, high treatment continuation rates, and low levels of regret after discontinuation suggest that regret after starting gender-affirming hormones is a relatively rare event. However, stability of gender identity before and after puberty among children and adolescents has not been assessed in a prospective manner.

In this issue of Pediatrics, Olsen et al32 describe the persistence of gender identity during the first 5 years of enrollment in a cohort of transgender children who completed a social transition before age 12. This study provides a detailed look at stability of transgender gender identity before and after the onset of puberty.32  The high persistence rates in this prospective study confirm previous findings and suggest that regret after starting gender-affirming treatment should be an uncommon event. This low risk of regret after gender-affirming treatment should reassure providers when recommending gender-affirming interventions to their patients. The low risk of regret should also inform the actions of legislators attempting to substitute their judgment for the judgment of patients, parents, and providers by denying transgender adolescents access to this evidence-based and potentially life-saving treatment.

COMPANION PAPER: A companion to this article can be found online at www.pediatrics.org/cgi/doi/10.1542/peds.2021-056082.

FUNDING: No external funding.

CONFLICT OF INTEREST DISCLAIMER: Dr Roberts has an investigator-initiated research grant from Organon Pharmaceuticals.

1
Zhang
Q
,
Goodman
M
,
Adams
N
, et al
.
Epidemiological considerations in transgender health: a systematic review with focus on higher quality data
.
Int J Transgend Health
.
2020
;
21
(
2
):
125
137
2
Klein
DA
,
Roberts
TA
,
Adirim
TA
, et al
.
Transgender children and adolescents receiving care in the US Military Health System
.
JAMA Pediatr
.
2019
;
173
(
5
):
491
492
3
Arnoldussen
M
,
Steensma
TD
,
Popma
A
,
van der Miesen
AIR
,
Twisk
JWR
,
de Vries
ALC
.
Re-evaluation of the Dutch approach: are recently referred transgender youth different compared to earlier referrals?
Eur Child Adolesc Psychiatry
.
2020
;
29
(
6
):
803
811
4
Wiepjes
CM
,
Nota
NM
,
de Blok
CJM
, et al
.
The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets
.
J Sex Med
.
2018
;
15
(
4
):
582
590
5
Vance
SR
Jr
,
Halpern-Felsher
BL
,
Rosenthal
SM
.
Health care providers’ comfort with and barriers to care of transgender youth
.
J Adolesc Health
.
2015
;
56
(
2
):
251
253
6
Gridley
SJ
,
Crouch
JM
,
Evans
Y
, et al
.
Youth and caregiver perspectives on barriers to gender-affirming health care for transgender youth
.
J Adolesc Health
.
2016
;
59
(
3
):
254
261
7
Snelgrove
JW
,
Jasudavisius
AM
,
Rowe
BW
,
Head
EM
,
Bauer
GR
.
“Completely out-at-sea” with “two-gender medicine”: a qualitative analysis of physician-side barriers to providing healthcare for transgender patients
.
BMC Health Serv Res
.
2012
;
12
(
1
):
110
8
Olson
KR
,
Durwood
L
,
DeMeules
M
,
McLaughlin
KA
.
Mental health of transgender children who are supported in their identities
.
Pediatrics
.
2016
;
137
(
3
):
e20153223
9
Hembree
WC
,
Cohen-Kettenis
PT
,
Gooren
L
, et al
.
Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society clinical practice guideline
.
J Clin Endocrinol Metab
.
2017
;
102
(
11
):
3869
3903
10
World Professional Association for Transgender Health
.
Standards of care for the health of transsexual, transgender, and gender nonconforming people
.
Available at: https://www.wpath.org/publications/soc. Accessed May 3, 2022
11
de Vries
AL
,
Steensma
TD
,
Doreleijers
TA
,
Cohen-Kettenis
PT
.
Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study
.
J Sex Med
.
2011
;
8
(
8
):
2276
2283
12
van der Miesen
AIR
,
Steensma
TD
,
de Vries
ALC
,
Bos
H
,
Popma
A
.
Psychological functioning in transgender adolescents before and after gender-affirmative care compared with cisgender general population peers
.
J Adolesc Health
.
2020
;
66
(
6
):
699
704
13
Turban
JL
,
King
D
,
Carswell
JM
,
Keuroghlian
AS
.
Pubertal suppression for transgender youth and risk of suicidal ideation
.
Pediatrics
.
2020
;
145
(
2
):
e20191725
14
Kuper
LE
,
Stewart
S
,
Preston
S
,
Lau
M
,
Lopez
X
.
Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy
.
Pediatrics
.
2020
;
145
(
4
):
e20193006
15
Achille
C
,
Taggart
T
,
Eaton
NR
, et al
.
Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of transgender youths: preliminary results
.
Int J Pediatr Endocrinol
.
2020
;
2020
:
8
16
Vrouenraets
LJJJ
,
de Vries
ALC
,
de Vries
MC
,
van der Miesen
AIR
,
Hein
IM
.
Assessing medical decision-making competence in transgender youth
.
Pediatrics
.
2021
;
148
(
6
):
e2020049643
17
Clark
BA
,
Virani
A
.
“This wasn’t a split-second decision”: an empirical ethical analysis of transgender youth capacity, rights, and authority to consent to hormone therapy
.
J Bioeth Inq
.
2021
;
18
(
1
):
151
164
18
Laidlaw
MK
,
Van Meter
QL
,
Hruz
PW
,
Van Mol
A
,
Malone
WJ
.
Letter to the editor: “Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline”
.
J Clin Endocrinol Metab
.
2019
;
104
(
3
):
686
687
19
Turban
JL
,
Kraschel
KL
,
Cohen
IG
.
Legislation to criminalize gender-affirming medical care for transgender youth
.
JAMA
.
2021
;
325
(
22
):
2251
2252
20
de Vries
ALC
,
Richards
C
,
Tishelman
AC
, et al
.
Bell v Tavistock and Portman NHS Foundation Trust [2020] EWHC 3274: Weighing current knowledge and uncertainties in decisions about gender-related treatment for transgender adolescents
.
Int J Transgend Health
.
2021
;
22
(
3
):
217
224
21
Drummond
KD
,
Bradley
SJ
,
Peterson-Badali
M
,
Zucker
KJ
.
A follow-up study of girls with gender identity disorder
.
Dev Psychol
.
2008
;
44
(
1
):
34
45
22
Steensma
TD
,
Biemond
R
,
de Boer
F
,
Cohen-Kettenis
PT
.
Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study
.
Clin Child Psychol Psychiatry
.
2011
;
16
(
4
):
499
516
23
Steensma
TD
,
McGuire
JK
,
Kreukels
BP
,
Beekman
AJ
,
Cohen-Kettenis
PT
.
Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study
.
J Am Acad Child Adolesc Psychiatry
.
2013
;
52
(
6
):
582
590
24
Wallien
MS
,
Cohen-Kettenis
PT
.
Psychosexual outcome of gender-dysphoric children
.
J Am Acad Child Adolesc Psychiatry
.
2008
;
47
(
12
):
1413
1423
25
Drescher
J
,
Byne
W
.
Gender dysphoric/gender variant (GD/GV) children and adolescents: summarizing what we know and what we have yet to learn
.
J Homosex
.
2012
;
59
(
3
):
501
510
26
Carmichael
P
,
Butler
G
,
Masic
U
, et al
.
Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK
.
PLoS One
.
2021
;
16
(
2
):
e0243894
27
Brik
T
,
Vrouenraets
LJJJ
,
de Vries
MC
,
Hannema
SE
.
Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria
.
Arch Sex Behav
.
2020
;
49
(
7
):
2611
2618
28
Roberts
CM
,
Klein
DA
,
Adirim
TA
,
Schvey
NA
,
Hisle-Gorman
E
.
Continuation of gender-affirming hormones among transgender adolescents and adults. [Published online ahead of print April 22, 2022]
.
J Clin Endocrinol Metab
.
doi:10.1210/clinem/dgac251
29
Turban
JL
,
Loo
SS
,
Almazan
AN
,
Keuroghlian
AS
.
Factors leading to “detransition” among transgender and gender diverse people in the United States: a mixed-methods analysis
.
LGBT Health
.
2021
;
8
(
4
):
273
280
30
Turban
JL
,
Carswell
J
,
Keuroghlian
AS
.
Understanding pediatric patients who discontinue gender-affirming hormonal interventions
.
JAMA Pediatr
.
2018
;
172
(
10
):
903
904
31
Turban
JL
,
Keuroghlian
AS
.
Dynamic gender presentations: understanding transition and “de-transition” among transgender youth
.
J Am Acad Child Adolesc Psychiatry
.
2018
;
57
(
7
):
451
453
32
Olson
KR
,
Durwood
L
,
Horton
R
,
Gallagher
NM
,
Devor
A
.
Gender identity 5 years after social transition
.
Pediatrics
.
2022
;
150
(
2
):
e2021056082